# The company must be covered by at least 4 of these 5 ratings for the calculation to be performed.

*biotech · news · 2026-03-23 · MarketScreener*

## Key points

- The Trader super rating integrates Global Valuation, EPS Revisions over 4 months, and Visibility metrics.
- The Investor super rating uniquely includes 1-year EPS Revisions alongside other composite financial metrics.
- The Global composite rating requires coverage by at least four out of five specific financial ratings.
- The Quality composite rating needs coverage by at least two of Capital Efficiency, Reporting Quality, and Financial Health.

Trader This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Investor This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Global This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions. Quality This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

[Read the full story on MarketScreener](https://www.marketscreener.com/news/gsk-s-antibody-drug-conjugate-for-small-cell-lung-cancer-secures-orphan-drug-designation-in-japan-ce7e5edcdd8ef623)

---

Canonical: https://newsio.io/n/5f0c5ed6-097b-41db-986f-8d9732f3c909/the-company-must-be-covered-by-at-least-4-of-these-5-ratings-for-the-calculation
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works